$46M Grant for Genetic Medicines Hub for Children
$46M Grant for Genetic Medicines Hub for Children
$46M Grant for Genetic Medicines Hub for Children
Key points
اہم نکات
मुख्य बातें
- The University of Oxford and Boston Children's Hospital will lead a new Genetic Medicines Hub after a $46 million multi-year grant, one of six research hubs in the Aligning Research to Impact Autism (ARIA) ecosystem.
- Working with the Jackson Laboratory and N=1 Collaborative, the hub will build a platform to design, test and speed up genetic medicines, including antisense oligonucleotide therapies, for children with genetic disorders that cause neurodevelopmental conditions, including profound autism.
- It will first focus on genes including ARID1B, CHD2, GRIN2B, RNU4-2, SCN2A and SLC6A1, working with patient advocacy groups and the ARIA IMPACT Network of hospitals running clinical trials.
- The University of Oxford and Boston Children's Hospital will lead a new Genetic Medicines Hub after a $46 million multi-year grant, one of six research hubs in the Aligning Research to Impact Autism (ARIA) ecosystem.
- Working with the Jackson Laboratory and N=1 Collaborative, the hub will build a platform to design, test and speed up genetic medicines, including antisense oligonucleotide therapies, for children with genetic disorders that cause neurodevelopmental conditions, including profound autism.
- It will first focus on genes including ARID1B, CHD2, GRIN2B, RNU4-2, SCN2A and SLC6A1, working with patient advocacy groups and the ARIA IMPACT Network of hospitals running clinical trials.
- The University of Oxford and Boston Children's Hospital will lead a new Genetic Medicines Hub after a $46 million multi-year grant, one of six research hubs in the Aligning Research to Impact Autism (ARIA) ecosystem.
- Working with the Jackson Laboratory and N=1 Collaborative, the hub will build a platform to design, test and speed up genetic medicines, including antisense oligonucleotide therapies, for children with genetic disorders that cause neurodevelopmental conditions, including profound autism.
- It will first focus on genes including ARID1B, CHD2, GRIN2B, RNU4-2, SCN2A and SLC6A1, working with patient advocacy groups and the ARIA IMPACT Network of hospitals running clinical trials.
The University of Oxford and Boston Children's Hospital will lead a new Genetic Medicines Hub after a $46 million multi-year grant, one of six research hubs in the Aligning Research to Impact Autism (ARIA) ecosystem. Working with the Jackson Laboratory and N=1 Collaborative, the hub will build a platform to design, test and speed up genetic medicines, including antisense oligonucleotide therapies, for children with genetic disorders that cause neurodevelopmental conditions, including profound autism. It will first focus on genes including ARID1B, CHD2, GRIN2B, RNU4-2, SCN2A and SLC6A1, working with patient advocacy groups and the ARIA IMPACT Network of hospitals running clinical trials.
The University of Oxford and Boston Children's Hospital will lead a new Genetic Medicines Hub after a $46 million multi-year grant, one of six research hubs in the Aligning Research to Impact Autism (ARIA) ecosystem. Working with the Jackson Laboratory and N=1 Collaborative, the hub will build a platform to design, test and speed up genetic medicines, including antisense oligonucleotide therapies, for children with genetic disorders that cause neurodevelopmental conditions, including profound autism. It will first focus on genes including ARID1B, CHD2, GRIN2B, RNU4-2, SCN2A and SLC6A1, working with patient advocacy groups and the ARIA IMPACT Network of hospitals running clinical trials.
The University of Oxford and Boston Children's Hospital will lead a new Genetic Medicines Hub after a $46 million multi-year grant, one of six research hubs in the Aligning Research to Impact Autism (ARIA) ecosystem. Working with the Jackson Laboratory and N=1 Collaborative, the hub will build a platform to design, test and speed up genetic medicines, including antisense oligonucleotide therapies, for children with genetic disorders that cause neurodevelopmental conditions, including profound autism. It will first focus on genes including ARID1B, CHD2, GRIN2B, RNU4-2, SCN2A and SLC6A1, working with patient advocacy groups and the ARIA IMPACT Network of hospitals running clinical trials.
Most read
سب سے زیادہ پڑھی گئی
सबसे ज़्यादा पढ़ी गई
- Loading...
Get news in your inbox
خبریں اپنے ان باکس میں حاصل کریں
खबरें अपने इनबॉक्स में पाएं
One email when new stories are published. No spam, unsubscribe anytime.
نئی خبریں شائع ہونے پر ایک ای میل۔ کوئی سپیم نہیں، کسی بھی وقت ان سبسکرائب کریں۔
नई खबरें प्रकाशित होने पर एक ईमेल। कोई स्पैम नहीं, कभी भी अनसब्सक्राइब करें।